{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:18:29Z","timestamp":1788970709964,"version":"build-2803163510"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fecal Microbiota Transplantation (FMT) has emerged as a highly effective treatment for recurrent\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection. It is also a promising therapeutic approach for other microbiome-related disorders. However, the safety and efficacy of FMT depend critically on rigorous donor screening and selection protocols. In this study, we developed and evaluated an optimized donor screening and selection workflow that integrates multistep pathogen detection, metagenomic and metabolomic profiling, and clinical compatibility assessment to enhance FMT safety and donor quality assessment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective cross-sectional study we evaluated 178 stool donor candidates using a novel screening algorithm, which combined extended medical history, blood and urine testing, stool metagenomics (16S rRNA gene sequencing) and metabolomics (short-chain fatty acids), and microbiological stool tests to exclude the stool samples with pathogens and ensure their microbial diversity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The FMT donor screening and selection workflow was developed and included four main steps: 1. Potential donors (\n                      <jats:italic>n<\/jats:italic>\n                      = 178) had to meet all the study inclusion criteria (47.8% of donors passed this screening step); 2. Potential donors (\n                      <jats:italic>n<\/jats:italic>\n                      = 85) underwent microbiological and microscopic stool examination (23% of initially enrolled donors passed this screening step). Most of the healthy donors were excluded at this selection step due to the abnormal values of\n                      <jats:italic>Enterococcus spp<\/jats:italic>\n                      . (47.1% of healthy donors had abnormal values), total number of\n                      <jats:italic>Enterobacteriaceae<\/jats:italic>\n                      and\n                      <jats:italic>Bifidobacterium spp<\/jats:italic>\n                      . (for both parameters 41.2% of healthy donors had abnormal values) abundance; 3. Potential donors (\n                      <jats:italic>n<\/jats:italic>\n                      = 41) underwent blood (total blood cell count, biochemical blood analysis) and urine (urinalysis) tests. Only 13 donors (7.3% of the initial cohort) proceeded to the final metabolomic analysis, resulting in the selection of 3 FMT donors (1.7% eligibility rate).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study establishes a data-driven, high-stringency donor selection framework that provides a rational basis for improving FMT safety and donor quality. Our findings advocate for the standardized implementation of advanced screening technologies, particularly SCFA metabolomics, as a critical quality control step in stool banking. While clinical validation of the efficacy-enhancing potential of this protocol requires prospective studies, the strong association between butyrate-producing microbiota and favorable FMT outcomes, combined with our previous clinical observations, supports the utility of our approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1927788","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:56:30Z","timestamp":1788969390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A multi-step screening algorithm for fecal microbiota transplantation donors: integrating metagenomic and metabolomic profiling for improved safety and donor quality assessment"],"prefix":"10.3389","volume":"17","author":[{"given":"Alina V.","family":"Gospodarik","sequence":"first","affiliation":[{"name":"Center of Molecular Medicine and Diagnostics, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay I.","family":"Khromykh","sequence":"additional","affiliation":[{"name":"Center of Molecular Medicine and Diagnostics, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia D.","family":"Prokhorova","sequence":"additional","affiliation":[{"name":"Center of Molecular Medicine and Diagnostics, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaroslav D.","family":"Shansky","sequence":"additional","affiliation":[{"name":"Center of Molecular Medicine and Diagnostics, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Balazs","sequence":"additional","affiliation":[{"name":"Center of Molecular Medicine and Diagnostics, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency","place":["Moscow, Russia"]},{"name":"Center for Bio- and Medical Technologies","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Bespyatykh","sequence":"additional","affiliation":[{"name":"Center of Molecular Medicine and Diagnostics, Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency","place":["Moscow, Russia"]},{"name":"Mendeleev University of Chemical Technology of Russia","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.22416\/1382-4376-2019-29-2-12-22","article-title":"Prospects of using microbiota correction methods in the treatment of inflammatory bowel disease","volume":"29","author":"Akinshina","year":"2019","journal-title":"Russ. J. Gastroenterol. Hepatol. Coloproctol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/MPG.0000000000001940","article-title":"Competitively selected donor fecal microbiota transplantation.","volume":"67","author":"Barnes","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0276323","DOI":"10.1371\/journal.pone.0276323","article-title":"Challenges and costs of donor screening for fecal microbiota transplantations","volume":"17","author":"B\u00e9nard","year":"2022","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cgh.10","article-title":"Gut microbiota features in relation to fecal microbiota transplantation outcome in ulcerative colitis: a systematic review and meta-analysis","volume":"23","author":"B\u00e9nard","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.17816\/clinpract275406","article-title":"Shansky Ya.D. fecal microbiota transplantation in the treatment of astrovirus infection in a recipient of an allogeneic hematopoietic stem cell transplant: a clinical case","volume":"14","author":"Bespyatykh","year":"2023","journal-title":"J Clin Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3390\/jcm9061757","article-title":"Fecal microbiota transplantation: screening and selection to choose the optimal donor","volume":"9","author":"Bibb\u00f2","year":"2020","journal-title":"J. Clin. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","article-title":"European consensus conference on faecal microbiota transplantation in clinical practice","volume":"66","author":"Cammarota","year":"2017","journal-title":"Gut"},{"key":"B8","doi-asserted-by":"publisher","first-page":"622949","DOI":"10.3389\/fcimb.2021.622949","article-title":"Stool banking for fecal microbiota transplantation: methods and operations at a large stool bank","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Cell. Infect. Microbiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1111\/cts.13113","article-title":"Data driven evaluation of healthy volunteer characteristics at screening for phase I clinical trials to inform on study design and optimize screening processes","volume":"14","author":"Deiteren","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"854545","DOI":"10.3389\/fphys.2022.854545","article-title":"Alterations of the gut microbiome and fecal metabolome in colorectal cancer: implication of intestinal metabolism for tumorigenesis","volume":"13","author":"Du","year":"2022","journal-title":"Front. Physiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"14494","DOI":"10.1038\/s41598-023-41182-6","article-title":"Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis","volume":"13","author":"Feng","year":"2023","journal-title":"Sci. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/ismej.2017.44","article-title":"Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation","volume":"11","author":"Fuentes","year":"2017","journal-title":"ISME J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19490976.2022.2125734","article-title":"Not just a gut feeling: a deep exploration of functional bacterial metabolites that can modulate host health","volume":"14","author":"Gold","year":"2022","journal-title":"Gut Microbes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12866-019-1689-y","article-title":"Long-term impact of fecal transplantation in healthy volunteers","volume":"19","author":"Goloshchapov","year":"2019","journal-title":"BMC Microbiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.14309\/ajg.0000000000002167","article-title":"Fecal microbiota transplantation across the lifespan: balancing efficacy, safety, and innovation","volume":"118","author":"Gulati","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12934-021-01705-0","article-title":"A comprehensive approach to stool donor screening for faecal microbiota transplantation in China","volume":"20","author":"He","year":"2021","journal-title":"Microb. Cell Fact"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1053\/j.gastro.2018.12.019","article-title":"Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent clostridium difficile infection","volume":"156","author":"Hvas","year":"2019","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(17)30338-2","article-title":"Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial","volume":"3","author":"Johnsen","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-016-0225-7","article-title":"Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study","author":"Kang","year":"2017","journal-title":"Microbiome"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/metabo12060525","article-title":"An improved method to quantify short-chain fatty acids in biological samples using gas chromatography\u2013mass spectrometry","volume":"12","author":"Kim","year":"2022","journal-title":"Metabolites"},{"key":"B21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cmet.2017.09.008","article-title":"Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition","volume":"26","author":"Kootte","year":"2017","journal-title":"Cell Metab."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336532","article-title":"Toward optimising and standardising donor screening for faecal microbiota transplantion","author":"Liu","year":"2025","journal-title":"Gut"},{"key":"B23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3390\/metabo12090834","article-title":"Microbial tryptophan metabolism tunes host immunity, metabolism, and extraintestinal disorders","volume":"12","author":"Liu","year":"2022","journal-title":"Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/j.1462-2920.2009.02066.x","article-title":"Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene","volume":"12","author":"Louis","year":"2010","journal-title":"Environ. Microbiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/19490976.2019.1611153","article-title":"In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation","volume":"11","author":"McSweeney","year":"2020","journal-title":"Gut Microbes"},{"key":"B26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.21518\/1561-5936-2017-11-46-51","article-title":"Pravovoye regulirovaniye otnosheniy s patsiyentami i dobrovol'tsami v klinicheskikh issledovaniyakh","volume":"11","author":"Melikhov","year":"2017","journal-title":"Remedium."},{"key":"B27","doi-asserted-by":"publisher","first-page":"111619","DOI":"10.1016\/j.biopha.2021.111619","article-title":"Role of microbiota-derived short-chain fatty acids in cancer development and prevention","volume":"139","author":"Mirzaei","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"661493","DOI":"10.3389\/fimmu.2021.661493","article-title":"Serum short-chain fatty acids and associations with inflammation in newly diagnosed patients with multiple sclerosis and healthy controls","volume":"12","author":"Olsson","year":"2021","journal-title":"Front. Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"424615","DOI":"10.3389\/fimmu.2019.00277","article-title":"Short chain fatty acids (SCFAs)mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases","volume":"10","author":"Parada Venegas","year":"2019","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1097\/MIB.0000000000000405","article-title":"Donor recruitment for fecal microbiota transplantation","volume":"21","author":"Paramsothy","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e13424","DOI":"10.1111\/ijcp.13424","article-title":"Why knowing healthy controls matters","volume":"74","author":"Pavletic","year":"2020","journal-title":"Int. J. Clin. Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.chom.2023.03.020","article-title":"Key determinants of success in fecal microbiota transplantation: from microbiome to clinic","volume":"31","author":"Porcari","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6837","DOI":"10.1007\/s00216-021-03639-3","article-title":"A highly sensitive, simple, and fast gas chromatography\u2013mass spectrometry method for the quantification of serum short-chain fatty acids and their potential features in central obesity","volume":"413","author":"Rahman","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-05470-4","article-title":"Microbial tryptophan catabolites in health and disease","volume":"9","author":"Roager","year":"2018","journal-title":"Nat. Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.clnu.2022.08.004","article-title":"Peanuts as a nighttime snack enrich butyrate-producing bacteria compared to an isocaloric lower-fat higher-carbohydrate snack in adults with elevated fasting glucose: a randomized crossover trial","volume":"41","author":"Sapp","year":"2022","journal-title":"Clin. Nutr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.24287\/1726-1708-2024-23-2-98-106","article-title":"Fecal microbiota transplantation for the treatment of intestinal diseases after allogeneic hematopoietic stem cell transplantation in children","volume":"23","author":"Seregin","year":"2024","journal-title":"Pediatr Hematol Oncol Immunopathol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"6333","DOI":"10.1007\/s00216-021-03589-w","article-title":"Sensitive and quantitative determination of short-chain fatty acids in human serum using liquid chromatography mass spectrometry","volume":"413","author":"Shafaei","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e70168","DOI":"10.1002\/mco2.70168","article-title":"Gut microbiota dysbiosis: pathogenesis, diseases, prevention, and therapy","volume":"6","author":"Shen","year":"2025","journal-title":"Med. Comm."},{"key":"B40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40168-020-0792-5","article-title":"Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study","volume":"8","author":"Sokol","year":"2020","journal-title":"Microbiome"},{"key":"B41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B42","article-title":"Fecal microbiota transplantation: therapeutical approaches and regulatory framework","author":"Vasilyev","year":"2015","journal-title":"Bioprep. Prev. Diagnosis, Treat."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fcimb.2019.00002;","article-title":"The super-donor phenomenon in fecal microbiota transplantation","volume":"9","author":"Wilson","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/19490976.2017.1286006","article-title":"Challenges in fecal donor selection and screening for fecal microbiota transplantation: a review","volume":"8","author":"Woodworth","year":"2017","journal-title":"Gut Microbes"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1097\/CM9.0000000000002421","article-title":"Metagenomic and targeted metabolomic analyses reveal distinct phenotypes of the gut microbiota in patients with colorectal cancer and type 2 diabetes mellitus","volume":"136","author":"Yang","year":"2023","journal-title":"Chin. Med. J"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e0157624","DOI":"10.1128\/spectrum.01576-24","article-title":"Unraveling the interplay between mesenchymal stem cells, gut microbiota, and systemic sclerosis: therapeutic implications","volume":"13","author":"Zhang","year":"2025","journal-title":"Microbiol. Spectr"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1927788\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:56:32Z","timestamp":1788969392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1927788\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":46,"alternative-id":["10.3389\/fmicb.2026.1927788"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1927788","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1927788"}}